Evidence Hub

Orexinergic modulation by Uwhangchungsimwon restores homeostasis of GABA/BDNF signaling in insomnia-depression comorbidity

Khoa Nguyen Tran, Y. A. Munni, Gia Linh Mac, Sarmin Ummey Habiba, Jin-Woo Jeong, Su Hui Seong, In-Jun Yang

Journal of Ethnopharmacology, 2026

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Uwhangchungsimwon (UCW) is a traditional East Asian multi-herbal formulation, used for managing stroke, convulsions, and mental confusion. Given the close association between stress, sleep disturbance, and mood disorders, UCW may hold therapeutic potential for insomnia-depression comorbidity, although its underlying mechanisms remain unclear. This study aims to explore the therapeutic potential of UCW for insomnia-depression comorbidity by targeting the orexinergic and GABAergic systems and identifying its bioactive compounds.

METHODS

In vivo experiments were performed in caffeine (CAF)-induced insomnia models of ICR mice, treated with CAF and UCW for 1 or 6 days. Sleep-wake patterns were monitored with the PiezoSleep system, and depression-like behaviors assessed using the Open Field Test (OFT) and Tail Suspension Test (TST). Hypothalamus and hippocampus from chronically exposed mice were analyzed for biomarker changes. To identify UCW's bioactive compounds, network pharmacology, molecular docking, molecular dynamics, DARTS assay, and calcium influx assay were employed.

RESULTS

UCW (400-800 mg/kg, po) markedly improved sleep-wake patterns, circadian rhythm, and depression-like behaviors in CAF-treated mice. CAF elevated serum corticosterone, hypothalamic orexin A, and OX1R, OX2R, GABABR1, BDNF, TNF-α, IL-6, and IL-1β levels in the hypothalamus and hippocampus, which were all reversed by UCW. In silico, in vitro, and in vivo analyses identified…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free